Targeting JAK-STAT with inhibitors for example ruxolitinib shows therapeutic potential, particularly in myeloproliferative neoplasms and leukemias, though challenges remain in understanding its full regulatory mechanisms and optimizing clinical applications (39). Here, SOAT1 is linked to leukemia.